You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Suppliers and packagers for generic pharmaceutical drug: ECONAZOLE NITRATE


✉ Email this page to a colleague

« Back to Dashboard


ECONAZOLE NITRATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Resilia Pharms ECOZA econazole nitrate AEROSOL, FOAM;TOPICAL 205175 NDA AUTHORIZED GENERIC Trifluent Pharma, LLC 73352-100-70 1 CANISTER in 1 CARTON (73352-100-70) / 70 g in 1 CANISTER 2025-09-13
Resilia Pharms ECOZA econazole nitrate AEROSOL, FOAM;TOPICAL 205175 NDA Resilia Pharmaceuticals, Inc. 81811-100-70 1 CANISTER in 1 CARTON (81811-100-70) / 70 g in 1 CANISTER 2023-12-04
Aurobindo Pharma Usa ECONAZOLE NITRATE econazole nitrate CREAM;TOPICAL 210364 ANDA Aurobindo Pharma Limited 59651-945-14 1 TUBE in 1 CARTON (59651-945-14) / 15 g in 1 TUBE 2026-03-13
Aurobindo Pharma Usa ECONAZOLE NITRATE econazole nitrate CREAM;TOPICAL 210364 ANDA Aurobindo Pharma Limited 59651-945-30 1 TUBE in 1 CARTON (59651-945-30) / 30 g in 1 TUBE 2026-03-13
Aurobindo Pharma Usa ECONAZOLE NITRATE econazole nitrate CREAM;TOPICAL 210364 ANDA Aurobindo Pharma Limited 59651-945-85 1 TUBE in 1 CARTON (59651-945-85) / 85 g in 1 TUBE 2026-03-13
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Supplier Landscape for Econazole Nitrate

Last updated: February 19, 2026

Econazole nitrate is an antifungal agent primarily used in topical formulations. The global supply chain involves multiple large-scale manufacturers and suppliers specializing in active pharmaceutical ingredients (APIs).

Major Manufacturers and Suppliers

Company Name Headquarters API Production Capacity Certification Notes
Synthesis Pharma India >50 tons/year cGMP, ISO 9001 Supplies to global markets; established player in antifungals
Fuso Pharmaceutical Co Japan Unknown cGMP Focuses on dermatological and antifungal APIs
Zhejiang Hisun Pharmaceutical China Unknown cGMP Increased capacity; export-oriented
Wuhan SOF Medichem China Unknown cGMP Major API producer; supplies global markets
Lekithos Pharma Greece Unknown cGMP Specializes in antifungal and dermatological APIs

Note: Exact production capacities are frequently confidential; these estimates derive from public reports and market analyses.

Availability Factors

Manufacturers such as Synthesis Pharma and Zhejiang Hisun have expanded capacities in recent years to meet rising global demand. Synthesis Pharma supplies primarily through third-party distribution, while Chinese manufacturers like Wuhan SOF Medichem mainly serve Asian markets but also export globally. Certification standards such as cGMP are common among major suppliers, ensuring compliance with international quality requirements.

Sourcing Channels

  • Direct Contracts: Large pharmaceutical companies and intermediaries often source directly from manufacturers, especially for bulk quantities.
  • Agencies and Distributors: Many companies utilize authorized distributors to secure supply chains, especially for smaller orders.
  • Third-party APIs: Some mid-sized suppliers produce econazole nitrate as part of a broader portfolio of antifungal APIs, competing on price and compliance standards.

Regulatory and Quality Considerations

  • Suppliers maintain certifications such as current Good Manufacturing Practices (cGMP) and ISO standards.
  • Exported APIs adhere to regulatory frameworks like the European Union's EMA, FDA, and corresponding Chinese and Indian standards.
  • Quality documentation, including certificates of analysis and batch records, are publicly available from established suppliers.

Market Dynamics and Trends

  • Growing demand for topical antifungal medications drives capacity expansion among Asian manufacturers.
  • Consolidation occurs in the API market, with larger players acquiring smaller companies to increase market share.
  • Supply disruptions are rare but can occur due to regulatory issues, manufacturing delays, or commodity price fluctuations.

Conclusion

The primary global suppliers for econazole nitrate are located in India, China, Japan, and Greece. Capacity and certification standards vary, but top-tier suppliers maintain compliance with international regulations. Buyers should prioritize suppliers with verified cGMP certification, reliable delivery records, and regulatory approvals consistent with target markets.

Key Takeaways

  • Major suppliers include Synthesis Pharma (India), Wuhan SOF (China), Zhejiang Hisun (China), and Lekithos Pharma (Greece).
  • Capacity ranges from moderate to high, with increasing investments in Asian markets.
  • Strict certification standards like cGMP are common among leading producers.
  • Procurement typically involves direct contracts or authorized distributors.
  • Supply chain stability hinges on regulatory compliance and quality assurance.

FAQs

Q1: How can I verify the quality of econazole nitrate supplied by a manufacturer?
Request Certificates of Analysis (COA), verify GMP certification, and conduct audits or third-party testing if necessary.

Q2: Are there regional differences in supplier quality standards?
Yes. European and North American suppliers often adhere to stricter standards than some Asian manufacturers, although many Chinese and Indian companies now comply with international cGMP standards.

Q3: What are the typical lead times for sourcing econazole nitrate?
Lead times generally range from 4 to 8 weeks, depending on supplier location, order volume, and regulatory approval processes.

Q4: Can I source econazole nitrate in small quantities?
Yes. Many suppliers provide smaller batch sizes through distribution channels, suitable for clinical trials or limited commercial use.

Q5: Is there a risk of supply shortages?
Supply is generally stable, but disruptions can occur due to regulatory issues, manufacturing setbacks, or sudden demand spikes. Establishing multi-source agreements mitigates this risk.


Citations:

[1] Market Research Future. (2022). Global Antifungal API Market Analysis.
[2] U.S. Food and Drug Administration. (2022). Current Good Manufacturing Practice (CGMP) Regulations.
[3] European Medicines Agency. (2022). API Manufacturing Standards.
[4] Company websites and industry reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.